The initiation of a new phase III clinical trial to evaluate one of the two late-stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer was announced. The clinical study, called LUME-Ovar-1 trial, investigates the compound BIBF 1120, a novel oral anti-angiogenic agent , for its efficacy and safety as first-line treatment in combination with standard chemotherapy compared to placebo in combination with standard chemotherapy in patients with advanced ovarian cancer.

Source:Medical News Today